Winona Safety, Regulation & Compliance: An Independent Clinical Review

Is Winona a Legitimate Medical Service?

Winona operates as a licensed telehealth practice. Its prescribers hold active state medical licenses, and the platform must meet the same standard-of-care obligations as any brick-and-mortar OB-GYN or internist managing menopause. That legal framework is real. The clinical question is whether its prescribing practices consistently reflect the current evidence base from The Menopause Society (TMS) and the FDA.

Medical Licensing and Prescribing Authority

Each state in which Winona operates requires its affiliated physicians to maintain active licenses in that state or to hold a valid interstate telehealth compact registration. Prescriptions for controlled substances must comply with the Ryan Haight Act and DEA telemedicine rules. Winona prescribes non-controlled hormones, so DEA registration is generally not the limiting factor here. State medical boards can investigate and sanction any physician practicing via telehealth on the same grounds applicable to in-person care, including inadequate history-taking or failure to obtain informed consent.

Compounding Pharmacy Oversight

Most of Winona's distinctive formulations, particularly custom-dose estradiol creams and testosterone preparations for women, come from 503A compounding pharmacies. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, these pharmacies may prepare patient-specific compounds without submitting new drug applications, but they must use USP-grade bulk ingredients, maintain sterile conditions where required, and comply with state board of pharmacy rules [1]. They are NOT required to demonstrate efficacy or safety through clinical trials before dispensing. That regulatory gap is material.

What Does the Evidence Say About Compounded Bioidentical HRT?

The phrase "bioidentical" refers to hormones chemically identical to those produced by the human ovary, chiefly 17-beta estradiol and micronized progesterone. Both are available as FDA-approved drugs (Estrace, Prometrium, transdermal patches). Winona's compounded versions carry the same active molecules but lack the post-market pharmacovigilance data that FDA-approved products accumulate over decades of prescribing.

FDA and TMS Positions on Compounded Hormones

The FDA has issued multiple guidance documents stating that compounded hormone therapy products have not been proven safe or effective, and that claims of superiority over approved products are not supported by evidence [2]. The Menopause Society's 2023 Position Statement states directly: "Compounded hormone therapy should not be used when FDA-approved hormone therapy is available and appropriate, because compounded therapies lack efficacy and safety data." [3]

That is a strong, evidence-based caution, not a ban. Compounded doses can serve patients who cannot tolerate standard commercial doses, or who need a delivery route not commercially available. But it is the exception, not the default starting point.

What the WHI and Subsequent Trials Actually Show

The Women's Health Initiative (WHI), which randomized 16,608 postmenopausal women to conjugated equine estrogen plus medroxyprogesterone acetate versus placebo, reported an increased hazard ratio for breast cancer of 1.26 (95% CI 1.00 to 1.59) at 5.6 years of follow-up [4]. That finding reshaped prescribing globally. Subsequent analysis clarified that the risk applied specifically to combined estrogen-progestogen therapy with synthetic progestins, not necessarily to micronized progesterone. The CECILE study and a large French cohort (E3N, N=80,377) found that women using transdermal estradiol combined with micronized progesterone had breast cancer risk not significantly different from non-users (RR 1.00, 95% CI 0.83 to 1.22 for micronized progesterone users at 5 years) [5]. This distinction matters for evaluating Winona, which favors micronized progesterone formulations.

Cardiovascular Risk by Timing

The "timing hypothesis," supported by re-analysis of WHI data and the KRONOS Early Estrogen Prevention Study (KEEPS), holds that women who initiate HRT within 10 years of menopause onset, or before age 60, have a more favorable cardiovascular risk profile than those who initiate later [6]. KEEPS (N=727, 4 years) found no progression of subclinical atherosclerosis in early initiators on transdermal estradiol or oral conjugated estrogen versus placebo [7]. Winona's intake questionnaires ask about time since menopause, but it is not publicly disclosed whether physicians apply a strict age-60 or 10-year cutoff as recommended by TMS guidelines.

Winona's Prescribing Model: What It Offers and Where Gaps Exist

Winona prescribes estradiol (oral, transdermal, vaginal, and cream), micronized progesterone, testosterone (off-label for women), DHEA, and some thyroid support. This is a reasonable formulary for menopause management. The clinical concern is not the drug list itself but the depth of baseline assessment conducted asynchronously or via short video visits.

Intake Evaluation Quality

TMS guidelines recommend that HRT candidates undergo a personal and family history for breast cancer, thromboembolic disease, cardiovascular disease, and stroke; a blood pressure measurement; and ideally a recent mammogram if age-appropriate [3]. A telehealth intake can capture most of this by questionnaire, but it cannot perform a physical exam or verify that a patient's last mammogram was truly negative. Winona relies on patient-reported history. That is standard for telehealth, and not unique to Winona, but patients with complex histories should understand this limitation.

Testosterone Prescribing for Women

No testosterone product is currently FDA-approved specifically for women in the United States [8]. Winona, like many HRT telehealth platforms, prescribes compounded low-dose testosterone for hypoactive sexual desire disorder (HSDD) or energy symptoms. The Global Consensus Statement on female testosterone use (2019, endorsed by TMS and the Endocrine Society) supports short-term use at physiologic premenopausal levels for HSDD in postmenopausal women, but stresses that long-term safety data beyond 24 months are limited [9]. Patients receiving testosterone from Winona should expect periodic total testosterone monitoring to confirm levels stay within the 15 to 70 ng/dL female reference range.

DHEA Prescribing

Intrarosa (prasterone 6.5 mg vaginal insert) is FDA-approved for dyspareunia due to vulvovaginal atrophy. Oral DHEA supplementation is a different matter. Oral DHEA converts to androgens and estrogens in peripheral tissues; the dose-response is unpredictable and varies widely by individual metabolism. The Endocrine Society's 2019 clinical practice guideline on DHEA states it does not recommend DHEA for general well-being in healthy adults, citing insufficient evidence [10]. Winona's use of oral DHEA for fatigue or mood symptoms in perimenopausal women sits outside this guideline recommendation.

How Winona Compares With Alternatives

The table below summarizes key regulatory and clinical differences between Winona and the primary alternatives available to menopausal women in the United States.

| Factor | Winona | Midi Health | Alloy Menopause | In-person OB-GYN | |---|---|---|---|---| | FDA-approved products available | Yes (some) | Yes | Yes | Yes | | Compounded HRT offered | Yes (primary model) | Yes | Limited | Varies by practice | | Insurance accepted | No | Some | No | Yes | | Physical exam performed | No | No | No | Yes | | Mammography verification | Patient-reported | Patient-reported | Patient-reported | Clinic can verify | | Testosterone for women | Yes (compounded) | Yes (compounded) | Limited | Varies | | Approximate monthly cost | $99 to $199 | $110 to $175 | $90 to $165 | Varies with insurance | | Synchronous physician visits | Yes (video) | Yes (video) | Yes (video) | Yes (in person) |

Midi Health and Alloy follow broadly similar telehealth models. The primary differentiator for any of these platforms versus in-person care is the absence of physical examination and the heavier reliance on compounded pharmacy networks. None of these platforms replaces the complete menopause evaluation described in TMS Practice Guidelines for conditions such as premature ovarian insufficiency, suspected pelvic pathology, or complex cardiovascular risk.

Safety Signals Specific to the Telehealth Compounding Model

Dose Inconsistency in 503A Compounding

A 2012 USP-commissioned analysis of compounded hormone preparations found that 34% of 29 tested samples failed content uniformity standards, meaning actual hormone dose deviated more than 10% from labeled dose [11]. More recent quality audits have shown improvement, but variability remains a concern compared with commercially manufactured products, which must meet FDA Current Good Manufacturing Practice (CGMP) standards. Patients using Winona's compounded creams should be aware that serum hormone levels may not match what the label predicts.

Lack of Long-Term Post-Market Data

FDA-approved HRT products such as Vivelle-Dot (transdermal estradiol) and Prometrium (oral micronized progesterone) carry decades of pharmacovigilance data. Compounded formulations with the same active molecules but different excipients, vehicles, or delivery concentrations do not. When a compounding pharmacy closes or reformulates, there is no equivalent of an FDA drug safety communication or label update. Patients bear the information asymmetry.

Absence of a Risk-Evaluation Framework Disclosure

Reputable menopause practices apply a structured absolute risk framework before initiating HRT, often using the TMS Menopause Hormone Therapy Decision Aid or the NICE menopause guideline risk stratification. Whether Winona's physicians systematically apply such a tool is not publicly documented. Patients with a first-degree relative with breast cancer, prior DVT, or hypertriglyceridemia warrant individualized risk-benefit analysis before starting any estrogen-containing therapy [3].

What Real-World Reviews Reveal

Patient reviews of Winona on independent platforms (Trustpilot, Reddit communities such as r/Menopause) cluster around two themes. Positive reviews cite convenience, responsive messaging, and symptom relief. Critical reviews most commonly describe difficulty reaching a physician for dose adjustments, unexpected price increases at refill, and receiving a compounded product when they requested FDA-approved alternatives. One recurring complaint is that some patients did not realize their prescription was compounded until they received the dispensed product. Transparent informed consent about the distinction between compounded and FDA-approved HRT should be standard at intake.

Clinical Recommendations for Prospective Winona Patients

Before starting any telehealth HRT service, including Winona, a patient should take the following concrete steps.

First, confirm whether the prescribed product is FDA-approved or compounded. Ask the physician directly and request the pharmacy's name and 503A registration number. Second, if you are 60 or older or more than 10 years past your last menstrual period, discuss the timing-hypothesis risk data with the prescribing physician before starting systemic estrogen. Third, ensure your most recent mammogram (if age 40 or older per USPSTF 2024 guidelines, which now recommend biennial screening starting at age 40) is on file and discussed [12]. Fourth, request baseline and 3-month follow-up serum levels for any testosterone or DHEA prescription. Fifth, if you have a personal or first-degree family history of breast cancer, thromboembolic disease, or cardiovascular disease, consider an in-person consultation with a menopause-certified physician (NCMP credential from TMS) before relying solely on a telehealth intake.

Winona can be a clinically appropriate starting point for healthy perimenopausal women with vasomotor symptoms and no significant risk factors. The platform is not appropriate as a substitute for comprehensive risk stratification in complex patients, and its compounding-first formulary requires patients to be more engaged and informed than they might need to be with a platform prescribing primarily FDA-approved therapies.

The single most evidence-supported HRT regimen for a woman aged 50 to 60 without a uterus remains transdermal 17-beta estradiol 0.05 to 0.1 mg/day. For a woman with a uterus, add oral micronized progesterone 100 to 200 mg nightly for endometrial protection, exactly as outlined in the TMS 2023 Position Statement [3]. Both of those products exist as FDA-approved drugs available through standard pharmacies at competitive cash prices, and that should be the first conversation with any prescribing physician, at Winona or elsewhere.